Literature DB >> 33934431

Correction.

.   

Abstract

Year:  2021        PMID： 33934431      PMCID： PMC8088953          DOI： 10.1111/cas.14922

Source DB:  PubMed          Journal:  Cancer Sci        ISSN： 1347-9032            Impact factor:   6.716


× No keyword cloud information.
  1 in total

1.  Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

Authors:  Makoto Nishio; Takashi Seto; Martin Reck; Edward B Garon; Chao-Hua Chiu; Kiyotaka Yoh; Fumio Imamura; Keunchil Park; Jin-Yuan Shih; Carla Visseren-Grul; Bente Frimodt-Moller; Annamaria Zimmermann; Gosuke Homma; Sotaro Enatsu; Kazuhiko Nakagawa
Journal:  Cancer Sci       Date:  2020-10-14       Impact factor: 6.716
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.